Welcome to our dedicated page for Biomea Fusion news (Ticker: BMEA), a resource for investors and traders seeking the latest updates and insights on Biomea Fusion stock.
Biomea Fusion, Inc. reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on oral small-molecule therapies for diabetes, obesity and related metabolic diseases. Its updates center on icovamenib, an investigational oral covalent menin inhibitor being evaluated in type 1 and type 2 diabetes, and BMF-650, an investigational oral GLP-1 receptor agonist candidate for obesity.
Recurring announcements include COVALENT trial results and study initiations, measures of beta-cell function, C-peptide, glycemic control and safety, scientific presentations at diabetes and metabolic-disease meetings, investor-conference activity, and periodic financial results with pipeline updates.
Biomea Fusion, Inc. (Nasdaq: BMEA) announced the successful closing of its initial public offering, selling 9,000,000 shares at $17.00 each, generating gross proceeds of $153 million. The shares began trading on the Nasdaq Global Select Market on April 16, 2021. The underwriters also received a 30-day option to purchase an additional 1,350,000 shares. J.P. Morgan Securities, Jefferies, and Piper Sandler served as joint book-running managers for this offering, which contributes to Biomea's mission in developing treatments for genetically defined cancers.
Biomea Fusion, Inc. (Nasdaq: BMEA) has priced its initial public offering (IPO) at $17.00 per share, offering 9,000,000 shares for a total of approximately $153.0 million in gross proceeds. The IPO will begin trading on the Nasdaq Global Select Market on April 16, 2021, and is set to close on April 20, 2021, pending customary conditions. Additionally, underwriters have a 30-day option to purchase up to 1,350,000 additional shares at the offering price. J.P. Morgan, Jefferies, and Piper Sandler are the joint book-running managers for the offering.